Finance Watch: Tetraphase Reorganization Follows Troubled Antibiotic Commercialization Path
Executive Summary
Tetraphase's plan to downsize may put the company on the same path as now-bankrupt Achaogen. Also, Bain raises $900m for its second life science fund, Provention calls off post-ADA offering and Oncologie raises $80m series B.
You may also be interested in...
AcelRx Obtains Troubled Antibiotic Firm Tetraphase In Stock Swap
Deal Snapshot: Unable to make a go of selling novel antibiotic Xerava, Tetraphase’s product and commercial team will be absorbed into AcelRx in $14.4m deal.
Finance Watch: Intrexon Reorganizes, Raises Cash And Becomes Precigen
The new year starts with a strategic shift by Intrexon. Also, Roivant and Sumitomo Dainippon launch Sumitovant, Melinta reorganizes through Chapter 11 bankruptcy, Acorda arranges debt relief and CF PharmTech raises a $90m series E round.
Multiple Alliances Expand Brii’s Commitment To Anti-Infectives
China-focused venture goes against tide by acquiring anti-infective assets via multiple deals that will build out its pipeline in an area deprioritized by big pharma.
Need a specific report? 1000+ reports available
Buy Reports